体内免疫细胞基因递送。

IF 7.1 2区 工程技术 Q1 BIOCHEMICAL RESEARCH METHODS
Jamison C Siebart , Ching S Chan , Xinyi Yao , Fang-Yi Su , Gabriel A Kwong
{"title":"体内免疫细胞基因递送。","authors":"Jamison C Siebart ,&nbsp;Ching S Chan ,&nbsp;Xinyi Yao ,&nbsp;Fang-Yi Su ,&nbsp;Gabriel A Kwong","doi":"10.1016/j.copbio.2024.103169","DOIUrl":null,"url":null,"abstract":"<div><p>Immune cell therapies are an emerging class of living drugs that rely on the delivery of therapeutic transgenes to enhance, modulate, or restore cell function, such as those that encode for tumor-targeting receptors or replacement proteins. However, many cellular immunotherapies are autologous treatments that are limited by high manufacturing costs, typical vein-to-vein time of 3–4 weeks, and severe immune-related adverse effects. To address these issues, different classes of gene delivery vehicles are being developed to target specific immune cell subsets <em>in vivo</em> to address the limitations of <em>ex vivo</em> manufacturing, modulate therapeutic responses <em>in situ</em>, and reduce on- and off-target toxicity. The success of <em>in vivo</em> gene delivery to immune cells — which is being tested at the preclinical and clinical stages of development for the treatment of cancer, infectious diseases, and autoimmunity — is paramount for the democratization of cellular immunotherapies.</p></div>","PeriodicalId":10833,"journal":{"name":"Current opinion in biotechnology","volume":null,"pages":null},"PeriodicalIF":7.1000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In vivo gene delivery to immune cells\",\"authors\":\"Jamison C Siebart ,&nbsp;Ching S Chan ,&nbsp;Xinyi Yao ,&nbsp;Fang-Yi Su ,&nbsp;Gabriel A Kwong\",\"doi\":\"10.1016/j.copbio.2024.103169\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Immune cell therapies are an emerging class of living drugs that rely on the delivery of therapeutic transgenes to enhance, modulate, or restore cell function, such as those that encode for tumor-targeting receptors or replacement proteins. However, many cellular immunotherapies are autologous treatments that are limited by high manufacturing costs, typical vein-to-vein time of 3–4 weeks, and severe immune-related adverse effects. To address these issues, different classes of gene delivery vehicles are being developed to target specific immune cell subsets <em>in vivo</em> to address the limitations of <em>ex vivo</em> manufacturing, modulate therapeutic responses <em>in situ</em>, and reduce on- and off-target toxicity. The success of <em>in vivo</em> gene delivery to immune cells — which is being tested at the preclinical and clinical stages of development for the treatment of cancer, infectious diseases, and autoimmunity — is paramount for the democratization of cellular immunotherapies.</p></div>\",\"PeriodicalId\":10833,\"journal\":{\"name\":\"Current opinion in biotechnology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2024-07-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0958166924001058\",\"RegionNum\":2,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0958166924001058","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

摘要

免疫细胞疗法是一类新兴的活体药物,依靠传递治疗性转基因来增强、调节或恢复细胞功能,如编码肿瘤靶向受体或替代蛋白的转基因。然而,许多细胞免疫疗法都是自体疗法,受制于高昂的制造成本、从静脉到静脉的典型时间(3-4 周)以及严重的免疫相关不良反应。为了解决这些问题,目前正在开发不同类别的基因递送载体,以体内特定免疫细胞亚群为靶点,从而解决体外制造的局限性,在原位调节治疗反应,并减少靶上和靶外毒性。体内免疫细胞基因递送--目前正处于临床前和临床开发阶段,用于治疗癌症、传染病和自身免疫--的成功对于细胞免疫疗法的民主化至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
In vivo gene delivery to immune cells

Immune cell therapies are an emerging class of living drugs that rely on the delivery of therapeutic transgenes to enhance, modulate, or restore cell function, such as those that encode for tumor-targeting receptors or replacement proteins. However, many cellular immunotherapies are autologous treatments that are limited by high manufacturing costs, typical vein-to-vein time of 3–4 weeks, and severe immune-related adverse effects. To address these issues, different classes of gene delivery vehicles are being developed to target specific immune cell subsets in vivo to address the limitations of ex vivo manufacturing, modulate therapeutic responses in situ, and reduce on- and off-target toxicity. The success of in vivo gene delivery to immune cells — which is being tested at the preclinical and clinical stages of development for the treatment of cancer, infectious diseases, and autoimmunity — is paramount for the democratization of cellular immunotherapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current opinion in biotechnology
Current opinion in biotechnology 工程技术-生化研究方法
CiteScore
16.20
自引率
2.60%
发文量
226
审稿时长
4-8 weeks
期刊介绍: Current Opinion in Biotechnology (COBIOT) is renowned for publishing authoritative, comprehensive, and systematic reviews. By offering clear and readable syntheses of current advances in biotechnology, COBIOT assists specialists in staying updated on the latest developments in the field. Expert authors annotate the most noteworthy papers from the vast array of information available today, providing readers with valuable insights and saving them time. As part of the Current Opinion and Research (CO+RE) suite of journals, COBIOT is accompanied by the open-access primary research journal, Current Research in Biotechnology (CRBIOT). Leveraging the editorial excellence, high impact, and global reach of the Current Opinion legacy, CO+RE journals ensure they are widely read resources integral to scientists' workflows. COBIOT is organized into themed sections, each reviewed once a year. These themes cover various areas of biotechnology, including analytical biotechnology, plant biotechnology, food biotechnology, energy biotechnology, environmental biotechnology, systems biology, nanobiotechnology, tissue, cell, and pathway engineering, chemical biotechnology, and pharmaceutical biotechnology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信